North America Minimal Residual Disease Testing Market Size, Share & Industry Trends Analysis Report By Application (Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others), By End User, By Technology, By Country and Growth Forecast, 2022 - 2028

The North America Minimal Residual Disease Testing Market would witness market growth of 13.0% CAGR during the forecast period (2022-2028).

The frequently prescribed surgeries to remove a tumor, along with additional complementary therapies, do not necessarily ensure the complete eradication of malignant cells. Malignances like cancer usually leave traces in human tissues and blood.

The diagnosis of these remaining cells is essential for determining whether more chemotherapy and radiation treatments are required. This has facilitated the use of MRD tests to clear any ambiguity regarding the presence of any residues of the disease. Additionally, extensive use has led to the development of non-invasive tests to identify MRD accurately.

The detection of patient-specific MRD by utilizing T-cell receptors (TCR) or immunoglobulin (IG) is becoming more common in leukemias without a chromosomal translocation or any leukemia-specific marker. In this instance, the TCR or IG's variable region is sequenced after the leukemic-specific TCR or IG clone is generated using PCR. Such sequences help in the formation of PCR primers that will only amplify the patient's particular leukemic clone.

In the United States of America, approximately 1,519,907 individuals either are living with or are in remission from lymphoma, myeloma, myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDS), or leukemia. Out of this, 186,400 were diagnosed with lymphoma, myeloma, or leukemia in 2021. According to the Leukemia & Lymphoma Society (LLS), this number accounts for 9.8% of the estimated overall cancer cases in the nation.

The US market dominated the North America Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $733.7 million by 2028.The Canada market is poised to grow at a CAGR of 15.6% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 14.5% during (2022 - 2028).

Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End User, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Global Minimal Residual Disease Testing Market is Estimated to reach $2.7 Billion by 2028, at a CAGR of 14.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Application

• Hematological Malignancies
• Leukemia
• Lymphoma
• Solid Tumors
• Others

By End User

• Hospitals & Specialty Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Others

By Technology

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Flow Cytometry
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Bio-Rad Laboratories, Inc.
• Guardant Health, Inc.
• Invitae Corporation (ArcherDX, Inc.)
• Bio-Techne Corporation
• F.Hoffmann-La Roche Ltd.
• ICON plc (MolecularMD Corporation)
• Natera, Inc.
• Sysmex Corporation
• Laboratory Corporation of America Holdings
• Invivoscribe, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Related Reports:

Global Minimal Residual Disease Testing Market Report 2022-2028

Europe Minimal Residual Disease Testing Market Report 2022-2028

Asia Pacific Minimal Residual Disease Testing Market Report 2022-2028

LAMEA Minimal Residual Disease Testing Market Report 2022-2028